Research
Hormonal
Multi-agonist therapies (GLP-1/GIP, GLP-1/Glucagon, GLP-1/GIP/Glucagon) do not inherently offer better tolerability than GLP-1 monotherapy; in fact, glucagon receptor activation may increase nausea and vomiting rates.
Do not assume that newer, multi-agonist weight loss drugs are easier on your stomach than older GLP-1 drugs. Some of these newer drugs actually cause more nausea because they target additional receptors that can trigger vomiting. You still need to start with a low dose and go slow, regardless of how many receptors the drug targets.
GoodRefutesHIGH confidence
In contrast, glucagon receptor activation is independently associated with nausea and vomiting through both central and peripheral mechanisms... Consequently, dual GLP-1/glucagon agonists survodutide, and triple GLP-1/GIP/glucagon agonists retatrutide are not spared gastrointestinal adverse events, as glucagon related pro-emetic signaling may offset any potential tolerability benefits from GIP agonism.
Why this rating
Based on clinical trial data cited for specific agents (Refs 12, 13, 21).
Source
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
Abdulhameed Alhazmi et al. · Frontiers in Endocrinology · 2026
DOI 10.3389/fendo.2026.1788698
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists induce nausea and vomiting primarily by binding to GLP-1 receptors in the dorsal vagal complex (brainstem) and stimulating peripheral vagal nerve fibers, leading to delayed gastric emptying and increased gut-to-brain signaling.Strong
- Flexible, gradual titration of GLP-1 receptor agonists significantly reduces nausea and vomiting rates and discontinuation compared to standard rapid titration without compromising weight loss efficacy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →